Silo Pharma, INC 8-K filings

Silo Pharma announced it has regained compliance with Nasdaq's minimum closing bid price requirement, a matter now considered closed by the exchange.

Silo Pharma, Inc. has filed a Certificate of Change to implement a 1-for-15 reverse stock split, effective June 2, 2026, adjusting its common stock structure and authorized shares.

Silo Pharma, Inc. will implement a 1-for-15 reverse stock split and reduce its authorized shares, effective June 2, 2026.

Silo Pharma's Board approved a $1 million share repurchase program and issued 848,320 common shares to an investor relations consultant as a $250,000 commitment fee.

Silo Pharma, Inc. has received an extension from Nasdaq until June 22, 2026, to regain compliance with the minimum $1.00 bid price requirement, avoiding immediate delisting.

Silo Pharma, Inc. shareholders approved an expanded equity incentive plan and granted the Board discretion to implement a reverse stock split at their annual meeting on October 24, 2025.

Silo Pharma, Inc. has closed a $2.5 million registered direct offering of common stock and warrants to institutional investors for working capital and general corporate purposes.

Silo Pharma, Inc. announced the launch of a cryptocurrency treasury strategy and the appointment of Corwin Yu to lead its new Crypto Advisory Board.

Silo Pharma, Inc. has acquired the r2crypto.com web-based application and associated domain names from MAVS Holdings LLC for 750,000 shares of its common stock.

Silo Pharma has entered into a new agreement with the University of Maryland, Baltimore, terminating a prior license and granting an exclusive evaluation license and option for intellectual property related to central nervous system-homing peptides for neuroinflammatory disease.

Silo Pharma, Inc. has received a notice from Nasdaq regarding non-compliance with the minimum $1.00 bid price requirement, initiating a 180-day period to regain compliance.

Silo Pharma successfully closes a $2 million public offering of common stock and warrants to bolster working capital.

Silo Pharma is advancing its pipeline of novel therapeutics, including psychedelic treatments, targeting underserved conditions like PTSD, fibromyalgia, Alzheimer's, and multiple sclerosis.

Silo Pharma, Inc. announces the grant of a U.S. patent for pharmacological prophylactics against stress-induced affective disorders in females, exclusively licensed from Columbia University.

Silo Pharma is progressing its lead assets, SPC-15 for PTSD and SP-26 for chronic pain, with IND submission for SPC-15 expected in 2025 and animal studies for SP-26 beginning in early 2025.

Silo Pharma's annual shareholder meeting resulted in the re-election of all board members, ratification of the auditor, and approval of executive compensation matters.

Silo Pharma has postponed its 2024 annual meeting of stockholders, rescheduling it for December 20, 2024, and establishing a new record date of November 12, 2024.

Silo Pharma is progressing its pipeline of novel therapeutics, including treatments for PTSD, chronic pain, Alzheimer's, and multiple sclerosis, with a focus on innovative drug delivery systems and streamlined regulatory pathways.

Silo Pharma has successfully completed a $2.1 million registered direct offering, alongside a concurrent private placement of warrants.

Silo Pharma has obtained an exclusive global license from Columbia University to develop and commercialize SPC-15, a novel intranasal treatment for PTSD and stress-induced anxiety disorders.

Silo Pharma has amended its Master License Agreement with the University of Maryland, Baltimore, updating the schedule of diligence milestones for licensed product development.

Silo Pharma has successfully completed a $2 million registered direct offering, priced at-the-market, to fund working capital and general corporate purposes.

Silo Pharma has submitted a pre-Investigational New Drug application to the FDA for its intranasal PTSD treatment, SPC-15, marking a significant step in its clinical development.

Silo Pharma's board has extended its stock repurchase program, allowing for up to $1 million in buybacks through April 30, 2024.

Silo Pharma is focusing its 2024 efforts on advancing four drug programs targeting mental health, chronic pain, and neurology, with a lead program for PTSD expected to reach the Pre-Investigational New Drug Application stage by the end of the second fiscal quarter.

Silo Pharma has extended its stock repurchase program, authorizing the purchase of up to $1 million of its common stock until March 31, 2024.